AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven <a target=_ ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...

New research shows that loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with facial changes ...

Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 ? February 1 in Paris, ...

Galderma Group AG operates as a dermatology ... Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin ...

These challenges have prompted Galderma to pursue a phase 4 study ... in combination with Sculptra, its poly-L-lactic acid dermal filler approved for the correction of cheek wrinkles, for the ...

1 HIT™ is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing ...

(BUSINESS WIRE )--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® LyftTM or ContourTM in combination with Sculptra® in patients ...

Galderma offers injections that help replace ... The filler brand, known as Sculptra, has launched a new product designed specifically for those who want to look like they have a better jawline ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments and boosting sales, according to dermatology group Galderma.

“There, people will need to use a filler.” Galderma’s most popular filler for weight loss drug users is a product called Sculptra, which was initially developed for HIV patients who ...